Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

March 30, 2026

Conditions

CancerNeoplasmsNeoplasms, BreastTumorPARPOvarian NeoplasmsProstatic CancerPancreatic CancerBreast CancerBiliary CancerColorectal Cancer

Interventions

DRUG

VB15010

Oral PARP1 inhibitor

Trial Locations (1)

RECRUITING

Cancer Hospital of Shandong First Medical university, Jinan

All Listed Sponsors

collaborator

Shandong Cancer Hospital and Institute

OTHER

lead

Shenzhen Yangli Pharmaceutical Technology Co., Ltd

INDUSTRY